|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007134,
umls-concept:C0014467,
umls-concept:C0021083,
umls-concept:C0021747,
umls-concept:C0021756,
umls-concept:C0030705,
umls-concept:C0205195,
umls-concept:C0205210,
umls-concept:C0231174,
umls-concept:C0443315,
umls-concept:C0445550,
umls-concept:C0681842
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2000-8-16
|
|
pubmed:abstractText |
The clinical and immunologic activities of interleukin-2 (IL-2) in cancer patients have been extensively studied and described; however, in most of these studies, IL-2 was administered by intravenous bolus or continuous infusion, while the immunologic effects of IL-2 given by the subcutaneous (s.c.) route have not yet been well studied.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0390-6078
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
298-303
|
|
pubmed:dateRevised |
2005-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10702820-Adult,
pubmed-meshheading:10702820-Aged,
pubmed-meshheading:10702820-Carcinoma, Renal Cell,
pubmed-meshheading:10702820-Complement C4,
pubmed-meshheading:10702820-Eosinophils,
pubmed-meshheading:10702820-Female,
pubmed-meshheading:10702820-Humans,
pubmed-meshheading:10702820-Immunotherapy,
pubmed-meshheading:10702820-Injections, Subcutaneous,
pubmed-meshheading:10702820-Interferons,
pubmed-meshheading:10702820-Interleukin-2,
pubmed-meshheading:10702820-Kidney Neoplasms,
pubmed-meshheading:10702820-Logistic Models,
pubmed-meshheading:10702820-Lymphocytes,
pubmed-meshheading:10702820-Male,
pubmed-meshheading:10702820-Middle Aged,
pubmed-meshheading:10702820-Prognosis,
pubmed-meshheading:10702820-Receptors, Interleukin-2,
pubmed-meshheading:10702820-Solubility,
pubmed-meshheading:10702820-T-Lymphocyte Subsets,
pubmed-meshheading:10702820-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients.
|
|
pubmed:affiliation |
Falck Division of Oncology, Niguarda-Ca' Granda Hospital, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article
|
